A single early warning signs (SEWS) system for recognizing clinically deterioration outperforms the national early warning score (NEWS) by having a lower activation threshold, broader clinical scope, and faster response time

单一早期预警信号(SEWS)系统在识别临床恶化方面优于国家早期预警评分(NEWS),因为它具有更低的激活阈值、更广泛的临床范围和更快的响应速度。

阅读:1

Abstract

BACKGROUND: The National Early Warning Score (NEWS) is a vital-signs point summation system developed to identify patients at risk of adverse events including cardiac arrests, unplanned ICU admissions, and deaths. The points are usually calculated by the Electronic Health Record after charting, recommending local actions and Rapid Response System (RRS) activation when reaching ≥ 7 points. NEWS, however, lacks consistent evidence that it improves outcome and may lead to alarm fatigue. At our institution we operate a Single Early Warning Signs (SEWS) system for RRS activation with a broader range of abnormal signs, without point summation, and bedside assessment within 10 min. METHODS: We analyzed 182 RRS activations using SEWS from July 1, 2022, to August 21, 2023, and compared the activation thresholds and dispositions that would have occurred had NEWS been used. FINDINGS: At the time of RRS activation using SEWS, only 10 patients (5.5%) had scored ≥ 7 NEWS points. Of the remaining 172 patients, 158 (86.8%) scored 0 to 4 NEWS points considered low risk and 14 (7.7%) scored 5 to 6 NEWS points considered medium risk (p < 0.001). Yet, 122 patients (67%) were transferred to a higher level of care including 58 patients (31.8%) to ICU. The median in-hospital cardiac arrest during the reported period was 0.8 per 1000 hospital admissions, which is substantially lower than reported rates. CONCLUSION: SEWS operating with a broader clinical scope, lower activation threshold, and faster RRS activation outperformed NEWS markedly reducing in-hospital cardiac arrests.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。